Oral Prenatal Tablets Where Unmetabolized Folic Acid Exposure Is Clinically Undesirable

The prenatal tablet application of L-5-MTHF calcium replaces folic acid at the same 0.4 mg or 1.0 mg unit dose and shifts stability control to the pre-blend stage because the reduced pteridine ring undergoes oxidative cleavage at the C9–N10 bond in the presence of oxygen, light, and acidic microenvironments. Tablets containing 0.4 mg or 1.0 mg levomefolate calcium per unit are manufactured to conform to USP <905> Uniformity of Dosage Units, USP <711> Dissolution, ICH Q3D elemental impurity limits, and 21 CFR 210/211 cGMP requirements for finished pharmaceuticals. In a direct compression format with a core weight of 300 mg, the API concentration is 0.133% w/w for the 0.4 mg dose and 0.333% w/w for the 1.0 mg dose; a 1:9 pre-blend of API with microcrystalline cellulose or mannitol is passed through a 600 µm stainless steel screen before the main blend to reduce assay variability at this low loading. Sodium ascorbate at 0.5–1.0% w/w is added as an oxygen scavenger, and the blend is processed at ≤40% RH and 18–22 °C to limit moisture uptake. Compression on a rotary tablet press at 10–20 kN produces cores with hardness 6–8 kP and friability ≤1.0% per USP <1216>. Dissolution testing uses USP <711> apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer at 37 ± 0.5 °C. The terminal dosage form is a film-coated tablet packaged in amber HDPE bottles with desiccant and induction-sealed liners; published data for the oxidative overage required at 24 months in this specific direct compression configuration is limited, so overages are justified by photostability and forced degradation data under ICH Q1A(R2) rather than by fixed industry defaults.

Unlike tablet manufacturing, capsule filling for L-5-MTHF calcium avoids compaction heat and permits a lower tapped density powder blend with antioxidant-rich excipients. Capsule products for folate deficiency associated with malabsorption and the MTHFR C677T polymorphism are formulated with 0.5 mg or 1.0 mg L-5-MTHF calcium per unit; with a 200 mg fill weight in a size 1 two-piece HPMC capsule, the API concentration is 0.25% w/w or 0.50% w/w. The pre-blend uses a 1:10 ratio of API to sodium ascorbate before geometric dilution with mannitol and croscarmellose sodium 2.0% w/w; colloidal silicon dioxide 0.5% w/w is added to improve flow. Blending is performed in a low-shear V-blender at 20 rpm for 15 min, followed by lubrication with magnesium stearate 0.5% w/w for 3 min. The lubricated blend is filled on a dosator-type capsule machine at ≤35% RH and 18–22 °C; weight sorting acceptance is ±5% of target fill weight. Compliance for the finished capsules includes USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and ICH Q3D elemental impurity limits; if the product is marketed as a prescription drug, 21 CFR 210/211 cGMP applies, whereas a medical food or dietary supplement classification may invoke 21 CFR 117 or 21 CFR 111. The terminal dosage form is a two-piece HPMC capsule packaged in cold-form aluminum blister with desiccant or in HDPE bottles with coil desiccant; the exclusion of lactose monohydrate is intentional because reducing sugars can form Maillard adducts with the glutamic acid moiety under humidity stress.

What Limits the Lyophilized Injectable Shelf Life of L-5-MTHF Calcium?

Lyophilized injectable presentations are not the default route for this API because the reduced pteridine ring degrades rapidly in aqueous solution via oxygen-dependent and photo-induced pathways; consequently, aseptic processing, nitrogen overlay, and lyophilization are necessary controls rather than optional unit operations. A parenteral batch is compounded in Water for Injection at 5–10 mg L-5-MTHF calcium per 10 mL Type I borosilicate vial, with mannitol at 4.0% w/v as the crystalline bulking agent and pH adjusted to 7.0–8.0 with sodium hydroxide; published data for this specific configuration is limited, but the pH window is derived from the known acid-sensitivity of the 5-methyltetrahydrofolate redox state. The solution is sparged with sterile nitrogen to dissolved oxygen below 0.5 mg/L, filtered through a 0.22 µm PVDF membrane, and filled under ISO 14644-1 Grade A conditions within EU GMP Annex 1. The batch must conform to USP <1> Injections for sterility and pyrogen limits, USP <85> Bacterial Endotoxins, USP <790> Visible Particulates, and USP <791> pH. Lyophilization uses a shelf freeze to −40 °C, a primary drying plateau at −20 °C and chamber pressure 100 mTorr, and secondary drying at 25 °C until cake moisture is below 1.0%. Finished vials are sealed with nitrogen headspace. The terminal dosage form is a lyophilized powder for reconstitution in 0.9% sodium chloride or 5% dextrose; because light accelerates degradation, the vials are packed in opaque secondary cartons.

For patients unable to swallow tablet cores or capsules, a granule presentation in low-moisture stick-pack format addresses both dosing flexibility and oxidative stability at the point of dispensing. Each 1.0 g sachet contains 0.4 mg or 1.0 mg L-5-MTHF calcium, corresponding to 0.04% w/w or 0.10% w/w; sodium ascorbate at 1.0% w/w and sodium citrate dihydrate at 0.5% w/w maintain a non-acidic microenvironment, while mannitol and xylitol function as bulking and taste-masking agents. Direct powder blending is preferred over wet granulation because the API degrades in aqueous granulating fluid at 60 °C; the pre-blend is passed through a 500 µm conical mill at 1500 rpm, blended in a bin blender at 12 rpm for 20 min, and then filled into aluminum foil stick packs under nitrogen at ≤30% RH with a jaw sealing temperature of 150–170 °C. The foil laminate includes a polyethylene inner layer and an aluminum foil barrier to control moisture vapour transmission rate below 0.1 g/m²/day. Compliance references include Ph. Eur. 2.9.40 Uniformity of Dosage Units, USP <711> Dissolution for the reconstituted suspension, ICH Q1A(R2) stability testing, and ICH Q3D elemental impurities; batch release also includes assay of the 5-methyltetrahydrofolate oxidation product content by HPLC. The terminal dosage form is a single-dose stick pack for direct oral administration or reconstitution in water, packed in a secondary aluminum pouch with oxygen absorber.

When 15 mg L-Methylfolate Calcium Is Compressed Into Medical Food Tablets

At 7.5 mg or 15 mg per unit, the formulation is no longer a trace-level blend problem; with a 400 mg core weight, the API concentration reaches 1.875% w/w or 3.75% w/w, shifting the homogeneity risk from analytical detection to antioxidant distribution and compression-induced degradation at particle-contact points. Sodium ascorbate at 2.0% w/w is used as the antioxidant; silicified microcrystalline cellulose and mannitol are the main fillers; croscarmellose sodium 3.0% w/w is the disintegrant. The API and sodium ascorbate are co-milled through a 1.0 mm screen before blending to create an antioxidant-coated particle surface. Blending is conducted in a tumble bin at 12 rpm for 20 min, with magnesium stearate 0.5% w/w added for the final 3 min. Compression on a high-speed rotary press at 20–35 kN produces tablet hardness of 8–12 kP, friability ≤0.5%, and disintegration time ≤15 min per USP <701>. Compliance for the finished medical food tablet includes USP <905> Uniformity of Dosage Units, USP <711> Dissolution, ICH Q3D elemental impurities, and 21 CFR 211 cGMP if the product carries a prescription label; if the product is classified as a dietary supplement under 21 CFR 111, that cGMP applies. The terminal dosage form is a polyvinyl alcohol-based film-coated tablet packaged in cold-form aluminum blister with desiccant; light-protective coating and packaging are required because the API undergoes rapid photodegradation in the ultraviolet range.

Combination B-Vitamin Tablets for Homocysteine Management and the Low-Dose Assay Challenge

Combining L-5-MTHF calcium with pyridoxine hydrochloride and methylcobalamin in a single tablet creates two process conflicts: the API is oxygen-sensitive and degrades in acidic microenvironments, while pyridoxine hydrochloride creates localized acidic microenvironments after wet contact; and the analytical assay must separate L-5-MTHF from its oxidation products at a unit dose of 0.4–1.0 mg. The formulation uses a separated pre-blend strategy: L-5-MTHF calcium 0.4 mg or 1.0 mg per tablet is pre-blended with sodium citrate dihydrate 1.0% w/w, mannitol, and sodium ascorbate 1.0% w/w, while pyridoxine hydrochloride 2.0 mg and methylcobalamin 0.5 mg are blended separately. The two fractions are combined in a low-shear tumble blender at 15 rpm for 10 min, then lubricated with magnesium stearate 0.5% w/w and compressed on a rotary tablet press at 15–22 kN. With a 500 mg core weight, the L-5-MTHF concentration is 0.08–0.20% w/w, requiring HPLC with UV detection at 290 nm or LC-MS/MS for content uniformity and degradation product quantification. Compliance includes USP <905> Uniformity of Dosage Units, USP <711> Dissolution in pH 6.8 phosphate buffer, ICH Q3D elemental impurities, and 21 CFR 210/211 cGMP. The terminal dosage form is a film-coated tablet packaged in amber glass bottles with desiccant and oxygen absorber; tablets are film-coated with a moisture-barrier coating to minimize pH-mediated degradation during storage.